


## SUPPLEMENTARY TABLES

Supplementary Table 1. *TSKU* expression in cancer vs. normal tissue in the oncomine database.

	Cancer types	<i>P</i> -value	Fold change	Rank (%)	Sample	Reference (PMID)
Bladder	Superficial Bladder Cancer	7.75E-10	2.406	12%	76	16432078
Brain	Glioblastoma	1.53E-06	7.145	4%	31	16204036
and CNS	Anaplastic Astrocytoma	4.04E-06	2.615	5%	42	16616334
	Oligodendroglioma	2.67E-06	2.661	8%	73	16616334
	Glioblastoma	3.59E-08	3.333	11%	104	16616334
	Brain Glioblastoma	4.85E-07	1.647	14%	552	TCGA
Breast	Tubular Breast Carcinoma	3.30E-10	-1.511	14%	211	22522925
	Medullary Breast Carcinoma	8.57E-06	-1.601	14%	176	22522925
Kidney	Renal Oncocytoma	2.07E-07	-1.542	9%	35	16115910
Liver	Hepatocellular Carcinoma	3.72E-27	-2.136	7%	445	21159642
	Hepatocellular Carcinoma	6.98E-07	-2.328	12%	179	12058060
Lung	Squamous Cell Lung Carcinoma	1.70E-09	1.962	6%	92	20421987
	Lung Adenocarcinoma	4.34E-10	1.952	8%	116	22613842
Sarcoma	Leiomyosarcoma	3.83E-06	-2.424	6%	35	20601955
Others	Yolk Sac Tumor, NOS	8.82E-07	2.723	3%	15	16424014
	Teratoma, NOS	1.65E-08	1.932	3%	20	16424014
	Mixed Germ Cell Tumor, NOS	8.76E-09	1.729	7%	47	16424014

**Supplementary Table 2. Associations between TSKU expression and prognosis of different cancers in the prognosScan database.**



**Supplementary Table 3. Associations between TSKU methylation and prognosis of different cancers in the methSurv database.**

